Alessandro Brunelli1, Gaetano Rocco2, Zalan Szanto3, Pascal Thomas4, Pierre Emmanuel Falcoz5. 1. Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK. 2. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. University of Pecs, Pecs, Hungary. 4. Aix-Marseille University & Hospitals System of Marseille, Marseille, France. 5. University Hospital Strasbourg, Strasbourg, France.
Abstract
OBJECTIVES: To evaluate the postoperative complications and 30-day mortality rates associated with neoadjuvant chemotherapy before major anatomic lung resections registered in the European Society of Thoracic Surgeons (ESTS) database. METHODS: Retrospective analysis on 52 982 anatomic lung resections registered in the ESTS database (July 2007-31 December 2017) (6587 pneumonectomies and 46 395 lobectomies); 5143 patients received neoadjuvant treatment (9.7%) (3993 chemotherapy alone and 1150 chemoradiotherapy). To adjust for possible confounders, a propensity case-matched analysis was performed. The postoperative outcomes (morbidity and 30-day mortality) of matched patients with and without induction treatment were compared. RESULTS: 8.2% of all patients undergoing lobectomies and 20% of all patients undergoing pneumonectomies received induction treatment. Lobectomy analysis: propensity score analysis yielded 3824 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the neoadjuvant group (626 patients, 16% vs 446 patients, 12%, P < 0.001), but 30-day mortality rates were similar (71 patients, 1.9% vs 75 patients, 2.0%, P = 0.73). The incidence of bronchopleural fistula and prolonged air leak >5 days were similar between the 2 groups (neoadjuvant: 0.5% vs 0.4%, P = 0.87; 9.2% vs 9.9%, P = 0.27). Pneumonectomy analysis: propensity score analysis yielded 1312 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the treated patients compared to those without neoadjuvant treatment (neoadjuvant 275 cases, 21% vs 18%, P = 0.030). However, the 30-day mortality was similar between the matched groups (neoadjuvant 68 cases, 5.2% vs 5.3%, P = 0.86). Finally, the incidence of bronchopleural fistula was also similar between the 2 groups (neoadjuvant 1.8% vs 1.4%, P = 0.44). CONCLUSIONS: Neoadjuvant chemotherapy is not associated with an increased perioperative risk after either lobectomy or pneumonectomy, warranting a more liberal use of this approach for patients with locally advanced operable lung cancer.
OBJECTIVES: To evaluate the postoperative complications and 30-day mortality rates associated with neoadjuvant chemotherapy before major anatomic lung resections registered in the European Society of Thoracic Surgeons (ESTS) database. METHODS: Retrospective analysis on 52 982 anatomic lung resections registered in the ESTS database (July 2007-31 December 2017) (6587 pneumonectomies and 46 395 lobectomies); 5143 patients received neoadjuvant treatment (9.7%) (3993 chemotherapy alone and 1150 chemoradiotherapy). To adjust for possible confounders, a propensity case-matched analysis was performed. The postoperative outcomes (morbidity and 30-day mortality) of matched patients with and without induction treatment were compared. RESULTS: 8.2% of all patients undergoing lobectomies and 20% of all patients undergoing pneumonectomies received induction treatment. Lobectomy analysis: propensity score analysis yielded 3824 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the neoadjuvant group (626 patients, 16% vs 446 patients, 12%, P < 0.001), but 30-day mortality rates were similar (71 patients, 1.9% vs 75 patients, 2.0%, P = 0.73). The incidence of bronchopleural fistula and prolonged air leak >5 days were similar between the 2 groups (neoadjuvant: 0.5% vs 0.4%, P = 0.87; 9.2% vs 9.9%, P = 0.27). Pneumonectomy analysis: propensity score analysis yielded 1312 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the treated patients compared to those without neoadjuvant treatment (neoadjuvant 275 cases, 21% vs 18%, P = 0.030). However, the 30-day mortality was similar between the matched groups (neoadjuvant 68 cases, 5.2% vs 5.3%, P = 0.86). Finally, the incidence of bronchopleural fistula was also similar between the 2 groups (neoadjuvant 1.8% vs 1.4%, P = 0.44). CONCLUSIONS: Neoadjuvant chemotherapy is not associated with an increased perioperative risk after either lobectomy or pneumonectomy, warranting a more liberal use of this approach for patients with locally advanced operable lung cancer.
Authors: Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Gideon M Blumenthal; Paul A Bunn; Jamie E Chaft; Caroline E McCoach; Edith A Perez; Giorgio V Scagliotti; David P Carbone; Hugo J W L Aerts; Dara L Aisner; Jonas Bergh; Donald A Berry; Anthony Jarkowski; Nicholas Botwood; Darren A E Cross; Max Diehn; Nicole L Drezner; Robert C Doebele; Collin M Blakely; Wilfried E E Eberhardt; Enriqueta Felip; Luca Gianni; Steven P Keller; Patrick J Leavey; Shakun Malik; Francesco Pignatti; Tatiana M Prowell; Mary W Redman; Naiyer A Rizvi; Rafael Rosell; Valerie Rusch; Dirk de Ruysscher; Lawrence H Schwartz; Rajeshwari Sridhara; Rolf A Stahel; Stephen Swisher; Janis M Taube; William D Travis; Patricia Keegan; Jacinta R Wiens; Ignacio I Wistuba; Murry W Wynes; Fred R Hirsch; Mark G Kris Journal: J Thorac Oncol Date: 2018-09-27 Impact factor: 15.609
Authors: Whitney S Brandt; Wanpu Yan; Jian Zhou; Kay See Tan; Joseph Montecalvo; Bernard J Park; Prasad S Adusumilli; James Huang; Matthew J Bott; Valerie W Rusch; Daniela Molena; William D Travis; Mark G Kris; Jamie E Chaft; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2018-10-10 Impact factor: 5.209
Authors: Sai Yendamuri; Adrienne Groman; Austin Miller; Todd Demmy; Mark Hennon; Elisabeth Dexter; Anthony Picone; Chukwumere Nwogu; Grace K Dy Journal: Eur J Cardiothorac Surg Date: 2018-03-01 Impact factor: 4.191
Authors: Francesco Leo; Piergiorgio Solli; Lorenzo Spaggiari; Giulia Veronesi; Filippo de Braud; Maria Elena Leon; Ugo Pastorino Journal: Ann Thorac Surg Date: 2004-01 Impact factor: 4.330
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Francesco Leo; Giuseppe Pelosi; Angelica Sonzogni; Marco Chilosi; Guido Bonomo; Lorenzo Spaggiari Journal: Lung Cancer Date: 2009-05-27 Impact factor: 5.705
Authors: Giorgio Lo Iacono; Elena Prisciandaro; Shehab Mohamed; Luca Bertolaccini; Lara Girelli; Giulia Sedda; Antonio Mazzella; Juliana Guarize; Stefano Donghi; Lorenzo Spaggiari Journal: Indian J Thorac Cardiovasc Surg Date: 2022-06-27
Authors: K Sinn; B Mosleh; A Steindl; S Zoechbauer-Mueller; K Dieckmann; J Widder; E Steiner; W Klepetko; K Hoetzenecker; V Laszlo; B Doeme; T Klikovits; M A Hoda Journal: ESMO Open Date: 2022-04-06